174 related articles for article (PubMed ID: 27120977)
1. BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.
Habata S; Iwasaki M; Sugio A; Suzuki M; Tamate M; Satohisa S; Tanaka R; Saito T
Int J Oncol; 2016 Jul; 49(1):402-10. PubMed ID: 27120977
[TBL] [Abstract][Full Text] [Related]
2. BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer.
Sugio A; Iwasaki M; Habata S; Mariya T; Suzuki M; Osogami H; Tamate M; Tanaka R; Saito T
Gynecol Oncol; 2014 Sep; 134(3):615-23. PubMed ID: 24992675
[TBL] [Abstract][Full Text] [Related]
3. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737.
Boiani M; Daniel C; Liu X; Hogarty MD; Marnett LJ
J Biol Chem; 2013 Mar; 288(10):6980-90. PubMed ID: 23341456
[TBL] [Abstract][Full Text] [Related]
4. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Croft A; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Carcinog; 2018 Feb; 57(2):284-294. PubMed ID: 29068469
[TBL] [Abstract][Full Text] [Related]
5. BAG3 (BCL2-associated athanogene 3) interacts with MMP-2 to positively regulate invasion by ovarian carcinoma cells.
Suzuki M; Iwasaki M; Sugio A; Hishiya A; Tanaka R; Endo T; Takayama S; Saito T
Cancer Lett; 2011 Apr; 303(1):65-71. PubMed ID: 21316839
[TBL] [Abstract][Full Text] [Related]
6. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
[TBL] [Abstract][Full Text] [Related]
7. Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death.
Kafara P; Icard P; Guillamin M; Schwartz L; Lincet H
J Ovarian Res; 2015 Jun; 8():36. PubMed ID: 26063499
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Bcl-2-Associated Athanogene-3 Can Enhance the Efficacy of BGJ398 via Suppressing Migration and Inducing Apoptosis in Gastric Cancer.
Li K; Deng X; Feng G; Chen Y
Dig Dis Sci; 2021 Sep; 66(9):3036-3044. PubMed ID: 33089486
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
[TBL] [Abstract][Full Text] [Related]
10. BAG3 promotes proliferation of ovarian cancer cells via post-transcriptional regulation of Skp2 expression.
Yan J; Liu C; Jiang JY; Liu H; Li C; Li XY; Yuan Y; Zong ZH; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1668-1678. PubMed ID: 28624440
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
Li N; Chen M; Cao Y; Li H; Zhao J; Zhai Z; Ren F; Li K
BMC Cancer; 2018 Aug; 18(1):793. PubMed ID: 30081850
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
[TBL] [Abstract][Full Text] [Related]
13. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
14. BAG3 epigenetically regulates GALNT10 expression via WDR5 and facilitates the stem cell-like properties of platin-resistant ovarian cancer cells.
Zhao FY; Zhang Q; Wang JM; Jiang JY; Huyan LY; Liu BQ; Yan J; Li C; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2021 Aug; 1868(9):119077. PubMed ID: 34111434
[TBL] [Abstract][Full Text] [Related]
15. microRNA-340 induces apoptosis by downregulation of BAG3 in ovarian cancer SKOV3 cells.
Qu F; Wang X
Pharmazie; 2017 Aug; 72(8):482-486. PubMed ID: 29441908
[TBL] [Abstract][Full Text] [Related]
16. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.
Karpel-Massler G; Shu C; Chau L; Banu M; Halatsch ME; Westhoff MA; Ramirez Y; Ross AH; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Jun; 6(16):14507-21. PubMed ID: 26008975
[TBL] [Abstract][Full Text] [Related]
18. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.
Peddaboina C; Jupiter D; Fletcher S; Yap JL; Rai A; Tobin RP; Jiang W; Rascoe P; Rogers MK; Smythe WR; Cao X
BMC Cancer; 2012 Nov; 12():541. PubMed ID: 23171055
[TBL] [Abstract][Full Text] [Related]
19. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
